Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Product information and disease descriptionPlace of product in therapyDisease description

Natural history, survival, and mortality

8 evidence topics · 8 sources

All-cause mortality: Sleep Heart Health Study, apneas and hypopneas with 4% desaturation

“We prospectively examined whether sleep-disordered breathing was associated with an increased risk of death from any cause in 6,441 men and women participating in the Sleep Heart Health Study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The apnea–hypopnea index (AHI) was defined as the number of apneas and hypopneas, each associated with a 4% or greater decrease in oxygen saturation, per hour of sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The average follow-up period for the cohort was 8.2 y during which 1,047 participants (587 men and 460 women) died. Compared to those without sleep-disordered breathing (AHI: <5 events/h), the fully adjusted hazard ratios for all-cause mortality in those with mild (AHI: 5.0–14.9 events/h), moderate (AHI: 15.0–29.9 events/h), and severe (AHI: ≥30.0 events/h) sleep-disordered breathing were 0.93 (95% CI: 0.80–1.08), 1.17 (95% CI: 0.97–1.42), and 1.46 (95% CI: 1.14–1.86), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Stratified analyses by sex and age showed that the increased risk of death associated with severe sleep-disordered breathing was statistically significant in men aged 40–70 y (hazard ratio: 2.09; 95% CI: 1.31–3.33). Measures of sleep-related intermittent hypoxemia, but not sleep fragmentation, were independently associated with all-cause mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote